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ABSTRACT
Stem cells and biomaterials have been studied for therapeutic cardiac repair. Previous studies have
shown the beneficial effects of platelet fibrin gel and cardiac stem cells when cotransplanted into
rodent hearts with myocardial infarction (MI). We hypothesized that matrix metalloproteinases
(MMPs) play an important role in such protection. Thus, the present study is designed to elucidate
theeffects ofMMP inhibitionon the therapeutic benefits of intramyocardial injectionofplatelet fibrin
gel spiked with cardiac stem cells (cell-gel) in a rat model of acute MI. In vitro, broad-spectrumMMP
inhibitorGM6001undermines cell spreadingand cardiomyocyte contraction. In a syngeneic ratmodel
ofmyocardial infarction,MMP inhibition blunted the recruitment of endogenous cardiovascular cells
into the injected biomaterials, therefore hindering de novo angiogenesis and cardiomyogenesis.
Echocardiography and histology 3 weeks after treatment revealed that metalloproteinase inhibition
diminished the functional and structural benefits of cell-gel in treating MI. Reduction of host angio-
genesis, cardiomyocyte cycling, and MMP-2 activities was evident in animals treated with GM6001.
Our findings suggest that MMPs play a critical role in the therapeutic benefits of platelet fibrin gel
spiked with cardiac stem cells for treating MI. STEMCELLS TRANSLATIONALMEDICINE 2016;5:793–803
SIGNIFICANCE
In this study, the effects of matrix metalloproteinase inhibition on the performance of platelet gel
spiked with cardiac stem cells (cell-gel) for heart regeneration are explored. The results demonstrate
that matrix metalloproteinases are required for cell-gel to exert its benefits in cardiac repair. Inhibi-
tion of matrix metalloproteinases reduces cell engraftment, host angiogenesis, and recruitment of
endogenous cardiovascular cells in rats with heart attack.
INTRODUCTION
Heart disease remains the number one cause of
death in developed countries, generating sub-
stantial socioeconomic costs [1]. A typical myo-
cardial infarction (MI) causes the death of
billions of cardiomyocytes and can further de-
velop into heart failure. Once failure occurs,
only palliative and sympathetic treatment op-
tions are available to patients.
Stem cells andbiomaterials are promising al-
ternatives to conventional pharmacologic thera-
pies for therapeutic cardiac repair [2, 3]. Because
of their minimally invasive nature, injectable bio-
materials are appealing choices to be adminis-
tered, alone or blended with stem cells [4, 5].
Numerous injectable biomaterials have been
studied for cardiac repair, including fibrin gel
[6], collagen [7], self-assembling peptides [8],
hydrogel [9], polypropylene [10], and decellularized
myocardium matrix [11]. Among them, platelet
fibrin gel (also known as platelet fibrin scaffold)
is an appealing choice for therapeutic develop-
ment because it can be easily produced from blood
as either an allogeneic or autologous product. Car-
diac stem cells (CSCs) have been proven to be safe
and effective in early phases of clinical trials for
treating myocardial infarction [12, 13]. Previous
studies from our group showed that injection of
platelet gel alone attenuated adverse left ventric-
ular remodeling and preserved cardiac function
in rats with acute MI [14], whereas injection of
platelet gel spikedwith CSCs had even better ther-
apeutic benefits [15]. It is unclear whether the
extra benefits were merely from the addition of
cardiac stem cells or complex interactions be-
tween the cells and the biomaterial.
Matrix metalloproteinases (MMPs) are a
family of structurally related, zinc-containing
enzymes that contribute to the degradation of
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extracellular matrix proteins and connective tissue proteins [16].
MMPs have vital roles in the development, physiology, and pa-
thology of the cardiovascular system by acting on cardiovascular
remodeling, atherosclerotic plaque formation and plaque insta-
bility, vascular smooth muscle cell migration, and restenosis
[17]. MMPs also play key roles in extracellular matrix catabolism
and activation and inactivation of cytokines, chemokines, growth
factors, and other proteinases at the cell surface and within the
extracellularmatrix. Their activities are tightly regulated in anum-
ber of ways, such as transcriptional regulation, proteolytic activa-
tion, and interaction with tissue inhibitors of metalloproteinases
[18]. In the wound healing response, MMP inhibition has a neg-
ative effect on cell phenotype and dynamics [19–21]. In the
CSC/platelet fibrin gel (cell-gel) system that we used for cardiac
repair, MMPs are likely to play an important role in promoting
CSCs to migrate outside of the gel and, conversely, recruiting en-
dogenous cardiomyocytes and endothelial cells into the gel. Thus,
we hypothesized that MMPs play an essential role in the thera-
peutic benefits of cell-gel in cardiac repair. In the present study,
we aimed to explore the therapeutic benefits of intramyocardial
injection of cell-gel (platelet fibrin gel spiked with CSCs) in a rat
model of acute MI with or without the broad-spectrumMMP in-
hibitor GM6001.
MATERIALS AND METHODS
Derivation of Platelet Fibrin Gel
Platelet fibrin gelwasderived fromtheveinbloodofWistar-Kyoto
(WKY) rats [22]. Under deep anesthesia (by inhalation of isoflur-
ane), an incision was created at the rat’s abdominal skin, and the
vena cava was located. Venous blood (3–5 ml) was drawn from
the vena cava. To stop the coagulation cascade, the bloodwas im-
mediately citrated with 10% (vol/vol) 10 mM sodium citrate
(Sigma-Aldrich, St Louis,MO, http://www.sigmaaldrich.com), fol-
lowed by centrifugation at 1,000 g for 10 minutes and collection
of the supernatant (platelet-containing plasma). Whole blood
samples were sealed and left at room temperature for a period
of 2 hours and placed overnight at 4°C to allow blood cells and
blood plasma to fractionate. Samples were then centrifuged at
1,000g for 10minutes, and the supernatantwas collected. Super-
natants were centrifuged for a second time at 1,000 g for 10min-
utes to remove any residual blood cells, and blood plasma was
pooled and frozen at 220°C. For gel formation, the prewarmed
platelet-containing plasma was mixed with prewarmed Dulbec-
co’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific
Life Sciences, Waltham, MA, http://www.thermofisher.com) at
a ratio of 1:1 (vol/vol) and returned to 37°C for ∼3–5 minutes
(Fig. 1). The calcium in DMEM reinitiates the coagulation process,
which leads to the formation of a stable gel.
Derivation of Rat CSCs
CSCswere derived from the hearts ofWKY rats using the reported
cardiospheremethod as previously described [23–27].Myocardi-
al specimens harvested fromWKY rats were cut into fragments of
,2 mm3, washed with phosphate-buffered saline, and partially
digested with collagenase (Sigma-Aldrich). The tissue fragments
were cultured as cardiac explants on a 0.5-mg/ml fibronectin
solution–coated surface in Iscove’s modified Dulbecco’s medium
(IMDM; Thermo Fisher Scientific Life Sciences) containing 20%
fetal bovine serum. A layer of stromal-like cells emerged from
the cardiac explant with phase-bright cells over them. The
explant-derived cells were harvested using TryPEL Select (under
direct visualization of no more than 5 minutes) (Thermo Fisher
Scientific Life Sciences). Harvested cells were seeded at a density
of 23 104 cells/ml in UltraLow Attachment flasks (Corning, Corn-
ing, NY, http://www.corning.com) for cardiosphere formation. In
∼3–7 days, explant-derived cells spontaneously aggregated into
cardiospheres. The cardiospheres were collected and plated onto
fibronectin-coated surfaces to generate cardiosphere-derived
CSCs. CSCs were embedded in the scaffold during gel formation
to become cell-gel (Fig. 1). The culture was maintained in IMDM
(Thermo Fisher Scientific Life Sciences) containing 10% fetal
bovine serum.
Cell proliferation, viability, and morphology in the gel were
characterized and comparedwith the control cells cultured on tis-
sue culture plates (TCPs). For cell proliferation, 13 104 rat CSCs
were cultured in 1 ml platelet fibrin gel and on TCPs for 7 days.
Representative cell cultures were then stained with Live/Dead
Viability/Cytotoxicity Kit (Thermo Fisher Scientific Life Sciences)
after 12 hours and 3 and 7 days. The number of live cells in three
randomized microscopic fields was counted. Cell numbers were
normalized to the numbers at 12 hours to generate a cell growth
curve. Similarly, for the viability assay, 13 104 rat CSCs were cul-
tured in platelet fibrin gel and on TCPs for 7 days and then stained
with the same Live/Dead Viability/Cytotoxicity Kit, based on
green fluorescent calcein-AM (live) and red fluorescent ethidium
homodimer-1 (dead). Cell morphology was characterized from
the same images using ImagePro software.
Culture of Neonatal Rat Cardiomyocytes or
Mononuclear Cells in Cell-Gel With orWithout GM6001
To examine the impact of MMP inhibitor GM6001 on cardio-
myocytes or bone marrow mononuclear cells (MNCs) cultured
in cell-gel, we cultured neonatal rat cardiomyocytes (NRCMs)
orMNCs in the cell-gel with GM6001 (EMDMillipore, Darmstadt,
Germany, http://www.emdmillipore.com/US/en) or a scrambled
control (GM6001Negative Control [NC]) from the same vendor at
a concentration of 20mM. These NRCMs andMNCs were derived
from the same strain of WKY rats from which the CSCs were de-
rived (Fig. 1), as previously described [28, 29]. The cells were in-
cubated at 37°C and 5% CO2. To distinguish between the NRCMs
or MNCs and CSCs in the gel, CSCs were prelabeled with green
fluorescent DiO and NRCMs or MNCs were stained with red
fluorescent CM-DiI (Thermo Fisher Scientific Life Sciences). To
evaluate cell-gel degradation under physiological conditions,
we measured the thickness of the gel/cell composite over time
by determining the z distance of cell distribution with a confocal
microscope.
Release of In Vitro Growth Factors
To study sustained release of growth factors, we collected condi-
tioned media at various time points (days 2, 5, 9, and 14), and
fresh media was added back into the well to be conditioned for
future collection. The concentrations of various growth factors
were determined with enzyme-linked immunosorbent assay kits
(R&D Systems, Minneapolis, MN, http://www.rndsystems.com).
Animal Models
All animal work is compliant with the Institutional Animal Care
and Usage Committee (IACUC, North Carolina State University).
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We used an acute MI model as previously described [30]. Female
WKY rats (8–10 weeks old; n = 55) underwent left thoracotomy
under general anesthesia, and MI was produced by permanent
ligation of the left anterior descending coronary artery. We de-
rived platelet fibrin gel and CSCs fromWKY rats and intramyocar-
dially injected them into the infarcted hearts of syngeneic
animals. In general, an apparent infarct area with pale gray color
was visible after ligation. The animals were immediately sub-
jected to intramyocardial injections with a 29-gauge needle
at four sites in the peri-infarct area, according to one of four
randomly assigned groups: (a) MI + control: injection of 150 ml
vehicle (DMEM); (b)MI+ cell-gel: injectionof 150ml platelet fibrin
gel containing 1million CSCs (75ml host plasmamixed with 75ml
prewarmed DMEM containing 1 million CSCs); (c) MI + cell-gel +
GM6001: injection of 150ml platelet fibrin gel containing 1million
CSCs plus daily intraperitoneal injections of 50 mg/kg GM6001;
and (d) MI + cell-gel + GM6001-NC: injection of 150 ml platelet fi-
brin gel containing 1 million CSCs plus daily intraperitoneal injec-
tions of 50 mg/kg GM6001-NC (Fig. 1).
Heart Morphometric Analysis
Animals were euthanized 3 weeks after various treatments, and
the hearts were harvested and prepared for cryosections. Sec-
tions every 100mm(10-mmthickness)wereprepared and stained
with Masson trichrome (six sections per heart, collected at
400-mmintervals) [23]. Imageswere acquiredwith aPathScan En-
abler IV slide scanner (Advanced Imaging Concepts, Princeton, NJ,
http://www.aic-imagecentral.com). From the stained images,
morphometric parameters including infarct size, infarct wall
thickness, and viable tissue in the risk area were measured using
ImageJ software (NIH, Bethesda, MD, http://imagej.nih.gov/ij).
Six measurements were averaged for each heart. Respectively, vi-
able (normal) tissue and scar (infarct) tissue could be distinguished
with redandblue underMasson trichrome staining. To evaluate in-
farct thickness, measurements of wall thickness were taken at the
thinnest part of the infarction and then averaged (six sections per
heart, collected at 400-mm intervals). Viable tissue, expressed as a
percentage of risk region, was calculated by the sum of red area in
the risk region (defined with previously published methods [23]).
Infarct size was calculated by the sum of blue area and expressed
as a percentage of total left ventricular area.
Histology
For immunohistochemistry, heart cryosections were fixed with
4% paraformaldehyde, permeabilized, and blocked with Protein
Block Solution (Dako, Carpinteria, CA, http://www.dako.com)
containing 1% saponin (Sigma-Aldrich) and then incubated with
the following antibodies overnight at 4°C: rabbit anti–von Wille-
brand factor (Abcam, Cambridge, MA, http://www.abcam.com),
mouse anti–a sarcomeric actin (Sigma-Aldrich), rabbit anti-Ki67
(Abcam), or fluorescein isothiocyanate (FITC)-conjugated isolec-
tin B4 (Vector Laboratories, Burlingame, CA, http://vectorlabs.
com). FITC- or Texas red secondary antibodies were used for de-
tection. Images were taken with a confocal microscopy system.
Cardiac Function Assessment
To access cardiac function, blinded echocardiography analysis
was performed by a single observer using a Vevo Imaging System
(VisualSonics, Toronto, ON, Canada, http://www.visualsonics.
com). Light general anesthesia was induced with isoflurane.
Two-dimensional long-axis images were recorded from the left
caudal (apical) view. left ventricular end diastolic volume (LVEDV)
and left ventricular end systolic volume (LVESV) were measured/
calculated from two-dimensional long-axis views taken through
the infarcted area. Left ventricular ejection fraction (LVEF) was
calculated as (LVEDV – LVESV/LVEDV)3 100%.
Tissue Western Blot Analysis
Myocardial samples from the peri-infarct area were collected,
lysed, and homogenized. Homogenates were centrifuged
at 10,000 relative centrifugal force for 10 minutes on ice,
Figure 1. Study design. CSCs and PFGwere harvested fromWKY rat hearts and venous blood, respectively. CSCswere embedded in the PFG to
form cell-gel. For in vitro studies, neonatal rat cardiomyocytes and BM-MNCswere cultured in cell-gel with or withoutMMP inhibitor GM6001.
In vivo studies involved testing the treatment effects of cell-gel with or without GM6001 in a ratmodel of myocardial infarction. Abbreviations:
BM-MNC, bone marrow mononuclear cell; CSC, cardiac stem cell; MMP, matrix metalloproteinase; PFG, platelet fibrin gel.
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supernatants were collected, and protein content was quantified
with a BCA Protein Assay (Thermo Fisher Scientific Life Sciences).
The equivalent of 15 mg total protein per lane was loaded onto
12% Precise Protein gels (Bio-Rad, Hercules, CA, http://www.
bio-rad.com) and transferred to polyvinylidene fluoride mem-
branes. Membranes were blocked with 5% nonfat milk and incu-
bated overnight with primary antibodies against b-actin (Cell
Signaling Technologies, Danvers, MA, http://www.cellsignal.com),
MMP-2 (Abcam), andMMP-3 (Abcam). Subsequently, the appro-
priate horseradish peroxidase-conjugated secondary antibodies
were used, and the blots were visualized with SuperSignal West
Femto substrate andexposed to theGel Doc XR System (Bio-Rad).
Quantitative analysis was performed with ImageJ software, and
expressions were first normalized to b-actin and then to the
MI + control group.
Statistical Analysis
All results are presented as mean 6 SD. Comparisons between
any two groups were performed with two-tailed unpaired Stu-
dent’s t test, except that statistical significance between baseline
and 3-week LVEFs was determined using two-tailed paired Stu-
dent’s t test. Comparisons among more than two groups were
performed with one-way analysis of variance followed by post
hoc Bonferroni correction. Differences were considerd statisti-
cally significant when p, .05.
RESULTS
Characterization of CSCs in Platelet Fibrin Gel
CSCs cultured in platelet fibrin gel exhibited distinct elongated
morphology compared with cells cultured on TCPs (Fig. 2A).
The proliferation rates of CSCs cultured in the platelet fibrin gel
were comparable to those cultured on TCPs (Fig. 2B). The Live/
Dead assay showed that CSCs cultured in platelet fibrin gel had
cell viability comparable to those cultured on TCPs (Fig. 2C),
whereas MMP inhibitor GM6001 reduced CSC viability in the
gel (supplemental online Fig. 1) (p , .05 compared with CSCs
treated with GM6001-NC).
Effects ofMMP Inhibition on Cardiomyocytes andMNCs
Cultured in Cell-Gel
Theelongated cellmorphologyofCSCs in theplatelet gel indicates
their ability to degrade and soften the surroundingmatrix.Mean-
while, we have found that the presence of CSCs in platelet fibrin
gel promotes cardiomyocyte spreading and contracting. Here we
characterized the morphology and function of NRCMs andMNCs
cultured in cell-gel (Fig. 3A, 3B) under MMP inhibition. Less
spreading of NRCMs or MNCs was confirmed in cell-gel with
MMP inhibitor GM6001 (Fig. 3E, 3F) than those in cell-gel with
GM6001-NC (Fig. 3C, 3D). Quantitative cell morphology analysis
revealed that GM6001 decreased cell body elongation (Fig. 3G)
and cardiomyocyte contraction (Fig. 3H) (p , .05). To evaluate
the effects of MMP on cell-gel degradation, we measured the
thickness of cell-gel over time by confocal microscopy. MMP in-
hibition slowed matrix degradation: larger thicknesses were
found in cell-gel treated with MMP inhibitor GM6001 at days 7
and14 (Fig. 3I) (p, .05).Meanwhile,wedetected that the release
of growth factors (namely vascular endothelial growth factor
[VEGF] and insulin-like growth factor 1 [IGF-1]) was persistently
blocked by MMP inhibitor GM6001 (Fig. 3J, 3K) (VEGF and IGF-
1, p , .01 on days 2 and 5 and p, .05 on days 9 and 14).
Effects of MMP Inhibition on Recruitment of
Endogenous Cells In Vivo
To confirm our findings in vivo, we examined the impact of MMP
inhibitor GM6001 on the integration of cardiomyocytes and en-
dothelial cells into the injected cell-gel in the post-MI heart
(Fig. 4A). To enable histologic detection, CSCs were prelabeled
with CM-DiI (Thermo Fisher Scientific Life Sciences). cell-gel
was intramyocardially injected into WKY rat hearts immediately
after MI, and animals were sacrificed 7 days later for histologic
examination.More cardiomyocytes (Fig. 4B, 4C, green) and endo-
thelial cells (Fig. 4G, 4H, green) could be detected residing in
cell-gel with GM6001-NC (Fig. 4B, 4G, red) than in cell-gel with
GM6001 (Fig. 4C, 4H, red). Quantitative analysis confirmed those
findings (Fig. 4D, 4I). Highermagnification revealed integration of
cardiomyocytes (Fig. 4E, 4F) and endothelial cells (Fig. 4J, 4K)
into the cell-gel with the presence of GM6001-NC or GM6001.
MMP inhibitor GM6001 diminished such integration between the
injected cell-gel and endogenous cells. Quantitative analysis
revealed decreased numbers of infiltrating cardiomyocytes
(supplemental online Fig. 2A) and endothelial cells (supplemental
online Fig. 2B) in the cell-gel withMMP inhibitor GM6001, whereas
GM6001-NC had no effects on cell integration (p, .05).
Heart Morphology and Cardiac Function
Adverse ventricular remodeling, indicated as dilated chamber
and thinning of infarctedwall, can lead toheart failure. Therefore,
prevention of adverse ventricular remodeling after a myocardial
infarction is a key strategy to attenuate the progress of heart fail-
ure. Masson trichrome staining permitted simultaneous detec-
tion of scar (blue) and healthy myocardial (red) tissues (Fig. 5A;
supplemental online Fig. 3). Snapshots of the infarcted area indi-
cated the amount of viable tissue in the risk area (Fig. 5B;
supplemental online Fig. 3). Consistent with our previous find-
ings, hearts injected with cell-gel exhibited less left ventricular
chamber dilatation and infarct wall thinning than those that
received control (vehicle) injection. MMP inhibitor GM6001
blunted the therapeutic benefits of cell-gel: compared with hearts
receiving cell-gel with GM6001, those that received cell-gel alone
or cell-gel with GM6001-NC showed smaller infarct size (Fig. 5C),
thicker infarcted walls (Fig. 5D), and more viable tissue (Fig. 5E).
As one of themost valuable indicators of therapeutic benefits clin-
ically, LVEF can evaluate the improvement or preservation of car-
diac function. There was no significant difference in LVEF among
the four treatmentgroupsatbaseline (4hours afterMI), suggesting
a comparable degree of initial injury (Fig. 5F). Over the next 3
weeks, LVEF declined progressively in the control group, whereas
injection of cell-gel or cell-gelwithGM6001-NC improved cardiac
functions. MMP inhibition (cell-gel plus GM6001) diminished
the functional benefits of cell-gel (Fig. 5G, blue bar). To facilitate
comparisons, we calculated the treatment effect, which reflects
the changes in LVEF at 3weeks relative to baseline. Control treat-
menthadanegative effect, as LVEFdecreasedover time; cell-gel +
GM 6001 showed some degree of LVEF preservation. In contrast,
MI hearts treated with cell-gel or cell-gel with GM6001-NC
exhibited sizable LVEF improvement (Fig. 5H). These results sug-
gest that MMP inhibition blunted the structural and functional
benefits of cell-gel injection.
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Effects of MMP Inhibition on Mechanisms Underlying
Cell-Gel-Mediated Cardiac Repair and Protection
We have shown in our previous work that CSCs exert the major-
ity of their therapeutic benefits through indirect regenerative
mechanisms (e.g., paracrine effects) [31, 32]. Two important in-
direct regenerative mechanisms of cell-gel are its ability to pro-
mote angiogenesis and cardiomyocyte proliferation [15]. Thus,
we exploredwhetherMMP inhibitor GM6001 altered the regen-
erative mechanisms of cell-gel in those two aspects. Three
weeks after MI, transplanted CSCs were identified with CM-
DiI fluorescence. Isolectin B4+ capillaries (Fig. 6A, 6C) and cycling
cardiomyocytes (ki67+/a-SA+) (Fig. 6D) were consistently de-
tected. The capillary density (percentages of Lectin B4+ capillar-
ies) and number of cycling cardiomyocytes (Ki67+/a-SA+) in the
peri-infarct zone from the cell-gel or cell-gel + GM6001-NC
group were significantly higher than those from the control or
cell-gel + GM6001 group (Fig. 6B, 6E), suggesting that MMP in-
hibition suppressed the proangiogenic and procardiomyogenic
effects of cell-gel. Ki67+ nuclei were detected in DiI+ cells,
suggesting that a portion of injected CSCs were proliferating
(supplemental online Fig. 4). Western blot analysis confirmed
that GM6001 treatment decreased expression of MMP-2 and
MMP-3 in the heart (p , .05) (Fig. 7).
DISCUSSION
CSCs have been developed for treating MI and heart failure over
the last decade. Animal studies and a proof-of-concept human
study support the notion that CSCs may benefit patients with
ischemic cardiomyopathy [26]. Platelet fibrin gel represents an
appealing choice of injectable biomaterial for heart repair be-
cause it is biodegradable, nontoxic, and nonimmunoreactive
and provides mechanical and biological support to the injured
heart. It has been previously reported in the same rat model of
MI studied here that CSCs transplanted in fibrin gel had a favor-
ableengraftment rate comparedwith those transplanted in saline
[33]. Our group has also reported in a mouse model of MI that
CSCs transplanted in another type of hydrogel had a 24-hour en-
graftment rate of∼40% versus∼5% transplanted in saline [34]. In
addition, we reported the reparative and protective effects of
platelet fibrin gel injection for the treatment of acute MI [14].
We further showed that transplantation of platelet fibrin gel
spiked with CSCs could boost structural and functional benefits
compared with bare gel injection [15]. MMPs are zinc-containing
calcium-dependent endopeptidases that are released as inactive zy-
mogens in a latent form [35]. MMPs and their tissue inhibitors reg-
ulate matrix degradation, which further affects cardiac fibrosis and
myocardial performance [35]. It hasbeen reported thatCSCs secrete
proteins andmicroRNAs to inhibit cardiac fibrosis and apoptosis and
enhance contractility and angiogenesis [36]. All these regenerative
pathways could be mediated by matrix modulation.
GM-6001 (ilomastat or gelardin), a broad-spectrumMMP in-
hibitor, has beenextensively used in various experimentalmodels
of disease. The present study, which assessed the impact ofMMP
inhibitor on the therapeutic performance of cell-gel in a ratmodel
of acuteMI, has several important implications. First, we demon-
strated that MMP inhibition could not only alter cell morphology
but also blunt the proliferation and viability of CSCs cultured in
platelet fibrin gel (supplemental online Fig. 1), suggesting that
Figure 2. Characterization of CSCs in platelet fibrin gel. (A): CSCs cultured in platelet fibrin gel exhibited distinct elongated morphology com-
paredwith control cells culturedonTCPsat days 0.5, 3, and7. (B):Proliferationof CSCs grown inplatelet fibrin gel (red line) or onTCPs (black line)
(n = 3). (C): Live/Dead assay showed that CSCs cultured in platelet fibrin gel (red line) at day 7 had cell viability (more calcein AM–positive cells)
comparable to those cultured on TCPs (black line) (n = 3). Scale bar = 50mm. p =NS indicates p. .05 comparedwith one another. Abbreviations:
CSC, cardiac stem cell; NS, not significant; PFG, platelet fibrin gel; TCP, tissue culture plate.
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MMPs are important for cells to maintain a healthy function in
matrix. Second, our in vitro results showed that MMP inhibitor
GM6001 slowed cell-gel degradation and decreased the secre-
tion of growth factors (e.g., VEGF and IGF-1) (Fig. 3). Consis-
tently, previous studies have shown that MMPs can mobilize
growth factors such as VEGF throughmodulating the extracel-
lular matrix [37, 38]. Third, we assessed the role of MMPs
in cell-gel-induced angiogenesis, cardiac function protection,
and adverse remodeling prevention after MI. Our results indi-
cated that MMP inhibitor GM6001 diminished the integration
of cardiomyocytes and endothelial cell into the cell-gel (Fig. 4
and supplemental online Fig. 2) and the therapeutic benefits
of cell-gel (Fig. 5 and supplemental online Fig. 3).
Meanwhile, our study revealed that CSCs in gel (cell-gel) pro-
moted angiogenesis and myocyte cycling, but MMP inhibition
suppressed the proangiogenic and procardiomyogenic effects
of cell-gel (Fig. 6). Previous studies have shown that MMPs can
facilitate stemcell differentiation through remodelingof extracel-
lular matrix [39], as well as promote epithelial cell ingression
throughMMP-mediated breakdown of the basement membrane
[40, 41]. Similarly, we postulated that MMP inhibitor may block
CSCs’ “matrix softener” function, which is essential for their mi-
gration and the integration of local cardiomyocytes and endothe-
lial cells into the injected gel. MMP inhibition blunted cell–cell
interaction between injected CSCs and endogenous cardiomyo-
cytes and endothelial cells, which has been proven to be essential
Figure 3. Effects of MMP inhibition on cardiomyocytes and MNCs cultured in cell-gel. (A, B): Schematic and fluorescent micrograph showing
neonatal rat cardiomyocytes (NRCMs, red [A] orMNCs, red [B]) stainedwith red fluorescent CM-DiI cultured in cell-gel (CSCs labeledwith green
fluorescent DiO). (C, E): Less spreading of NRCMs (red, yellow outline) were confirmed in cell-gel (CSCs, green) containing MMP inhibitor
GM6001 (E) than those in cell-gel with GM6001 scrambled control (C). (D, F): Less spreading of MNCs (red, yellow outline) were confirmed
in cell-gel (CSCs, green) containing MMP inhibitor GM6001 (F) than those in cell-gel with GM6001 scrambled control (D). (G):Quantitative cell
morphology analysis showing cell bodyareaofNRCMscultured in cell-gelwithMMP inhibitorGM6001 (redbar) orGM6001-NC (bluebar) (n=4).
(H): Percentage of beating NRCMs in cell-gel containing GM6001 (red bar) or scrambled control (blue bar) (n = 3). (I) Thickness of cell-gel with
MMP inhibitor GM6001 (red line) or GM6001-NC (blue line) decreased over time in culture (n = 3 per time point). (J, K) Concentrations of VEGF
and IGF-1 in conditionedmedia of cell-gel withMMP inhibitor GM6001 (red bar) or GM6001-NC (blue bar) at various time points (n = 3 per time
point) determined by enzyme-linked immunosorbent assay. Scale bar = 10 mm. p, p, .05, pp, p, .01 compared with the GM6001-NC group.
Abbreviations: a.u., arbitrary unit; CSC, cardiac stem cell; IGF-1, insulin-like growth factor 1; NC, negative control; MMP, matrix metalloprotei-
nase; MNC, bone marrow mononuclear cell; NRCM, neonatal rat cardiomyocyte; VEGF, vascular endothelial growth factor.
798 Effects of MMPs on Cell-Gel in Heart Repair
©AlphaMed Press 2016 STEM CELLS TRANSLATIONAL MEDICINE
Figure 4. Effects of MMP inhibition on recruitment of endogenous cells to cell-gel. (A): Schematic showing endogenous cell integration with
injected cell-gel. (B) and (C): Cardiomyocytes stainedwitha-sarcomeric actin (green) populating the injected cell-gel, treated with GM6001-NC
([B], red) or cell-gel with GM6001 ([C], red) 7 days after injection. (D):Quantitation of cardiomyocytes infiltrating into the cell-gel (n = 3 animals
per group). (E, F): High-magnification images of the white box area in B and C. (G, H): Endothelial cells stained with vWF (green) populating the
injected cell-gel, treatedwith GM6001-NC ([E], red) or cell-gel with GM6001 ([F], red) 7 days after injection. (I):Quantitation of endothelial cells
infiltrating into injected cell-gel (n = 3 animals per group). (J, K):High-magnification images of thewhite box area in (G) and (H). Scale bar = 100mm.
p, p, .05 compared with MI + cell-gel + GM6001-NC group. Abbreviations: alpha-SA, a-sarcomeric actin; CSC, cardiac stem cell; MI, myocardial
infarction; MMP, matrix metalloproteinase; NC, negative control; vWF, von Willebrand factor.
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for CSC-mediated cardiomyogenesis and angiogenesis [42]. In ad-
dition, GM6001 is a broad-spectrum MMP inhibitor, targeting
MMP-1, -2, -3, -7, andmany others. We have previously reported
that MMP-2 andMMP-3 were secreted by CSCs and likely to play
positive roles in post-MI heart regeneration [43]. Here, we con-
firmed the decreased expressions of MMP-2 and MMP-3 in ani-
mals treated with GM6001 (Fig. 7).
Nevertheless, our study has several limitations. First, we did
not elucidate the roles of individualMMP subtypes (e.g., MMP-2,
MMP-3) in cell-gel-mediated heart repair. In addition, we used
echocardiographic results obtained from 4 hours post-MI as
the postinjury baseline. An echocardiography measurement
before MI surgery would rule out any congenital differences in
cardiac functions in different animals. Moreover, to obtain an
accurate cell survival/engraftment rate, quantitative methods
such as polymerase chain reaction (e.g., on SRY in the case of
male-to-female transplantation) are needed. Nevertheless, our
previous report in the same rat model of MI showed that CSCs
Figure 5. Heart morphometry and cardiac function. (A): Representative Masson trichrome–stained myocardial sections 3 weeks after treat-
ment with control (vehicle), cell-gel alone, cell-gel with GM6001, or cell-gel with GM6001-NC. Scar tissue and viable myocardium are identified
by blue and red, respectively. (B): Snapshots of the infarcted area. (C–E): Quantitative analysis of infarct size, infarct wall thickness, and viable
tissuepercentages fromMasson trichrome–stained images (n=5animals per group). (F,G): LVEFwasmeasuredbyechocardiography atbaseline
(4 hours afterMI) (F) and 3weeks later (G) (n = 6–7 animals per group). (G): Treatment effects (change in LVEF at 3weeks relative to baseline, in
each group). Scale bar = 2 mm. p, p, .05 compared with MI + control group; #, p, .05 compared with MI + cell-gel + GM6001 group. Abbre-
viations: LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NC, negative control.
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Figure 6. Effects of matrix metalloproteinasesinhibition on cell-gel-mediated cardiac repair mechanisms. (A): Injected cell-gel (CSCs labeled
with DiI, red) were surrounded by capillaries (stained with FITC-lectinB4, green) in the post-MI heart. (B): Quantification of capillary density
(percentages of Lectin B4+ capillaries) in hearts treated with control (vehicle), cell-gel alone, cell-gel + GM6001, and cell-gel + GM6001-NC
(n = 5 animals per group). (C):High-magnification images of thewhite box area in (A). (D): Ki67+ cardiomyocytes were detected in hearts treated
with cell-gel. (E): Quantification of cycling cardiomyocytes (Ki67+/a-SA+) in hearts treated with control (vehicle), cell-gel alone, cell-gel +
GM6001, and cell-gel + GM6001-NC (n = 5 animals per group). Scale bar = 50 mm. p, p , .05 compared with MI + control group; #, p , .05
comparedwithMI+ cell-gel +GM6001group.Abbreviations:a-SA,a-sarcomeric actin;CSC, cardiac stemcell;DAPI, 49,6-diamidino-2-phenylindole;
FITC, fluorescein isothiocyanate; MI, myocardial infarction; NC, negative control.
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transplanted in fibrin gel had a favorable engraftment rate com-
pared with those transplanted in saline [33], and the scrambled
drug GM6001-NC had no effect on the performance of cell-gel
compared with cell-gel alone (supplemental online Fig. 2; cell-gel
alone group reproduced from Cheng et al. [15]). In addition, the
toxic effects of the scrambled control on cardiomyocyte viability
and function in vitro need to be explored further.
CONCLUSION
Our study demonstrates thatMMPplays a critical role in the ther-
apeutic benefits of platelet fibrin gel spiked with cardiac stem
cells for treating myocardial infarction. Our findings provide im-
petus for further investigation of the synergistic effects of cell-
gel and MMPs in treating myocardial infarction.
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